BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34924268)

  • 1. Development and evaluation of the clinimetric properties of the Medication-Related Osteonecrosis of the Jaw Quality of Life Questionnaire (MRONJ-QoL).
    El-Rabbany M; Blanas N; Sutherland S; Shah PS; Lam DK; Azarpazhooh A
    Int J Oral Maxillofac Surg; 2022 Jun; 51(6):768-775. PubMed ID: 34924268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical Therapy in Patients With Medication-Related Osteonecrosis of the Jaw Is Associated With Disease Resolution and Improved Quality of Life: A Prospective Cohort Study.
    El-Rabbany M; Blanas N; Sutherland S; Lam DK; Shah PS; Azarpazhooh A
    J Oral Maxillofac Surg; 2022 Jun; 80(6):1084-1093. PubMed ID: 35183496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw.
    de Cassia Tornier S; Macedo FJ; Sassi LM; Schussel JL
    Support Care Cancer; 2021 Nov; 29(11):6713-6719. PubMed ID: 33973080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis.
    Murphy J; Mannion CJ
    Br J Oral Maxillofac Surg; 2020 Jul; 58(6):619-624. PubMed ID: 32247520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting the quality of life of patients with medication-related osteonecrosis of the jaw during treatment: A quality-of-life survey and causal analysis.
    Munakata K; Miyashita H; Yamada Y; Soma T; Iwasaki R; Nakagawa T; Asoda S
    J Craniomaxillofac Surg; 2024 Jun; 52(6):715-721. PubMed ID: 38582669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study.
    Capocci M; Romeo U; Guerra F; Mannocci A; Tenore G; Annibali S; Ottolenghi L
    Clin Ter; 2017; 168(4):e253-e257. PubMed ID: 28703840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw.
    Moll S; Mueller S; Meier JK; Reichert TE; Ettl T; Klingelhöffer C
    Oral Maxillofac Surg; 2021 Sep; 25(3):359-366. PubMed ID: 33226530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which symptoms negatively affect the oral health-related quality of life in patients with osteonecrosis of the jaw?
    Sato T; Kusumoto J; Takeda D; Kishimoto M; Kashin M; Furudoi S; Akashi M
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Aug; 130(2):175-180. PubMed ID: 32493679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals.
    Miranda-Silva W; Montezuma MA; Benites BM; Bruno JS; Fonseca FP; Fregnani ER
    Support Care Cancer; 2020 Nov; 28(11):5397-5404. PubMed ID: 32144584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review.
    Yamada SI; Kurita H; Kondo E; Suzuki S; Nishimaki F; Yoshimura N; Morioka M; Ishii S; Kamata T
    Clin Oral Investig; 2019 Aug; 23(8):3203-3211. PubMed ID: 30406491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress in the treatment and prevention of medication-related osteonecrosis of the jaw].
    Xu LC; Li YF
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2020 Jul; 55(7):509-514. PubMed ID: 32634892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
    Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
    Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England.
    Sturrock A; Preshaw PM; Hayes C; Wilkes S
    BMJ Open; 2019 Mar; 9(3):e024376. PubMed ID: 30833319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
    Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
    Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
    [No Abstract]   [Full Text] [Related]  

  • 17. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review.
    Cavalcante RC; Tomasetti G
    J Craniomaxillofac Surg; 2020 Nov; 48(11):1080-1086. PubMed ID: 32998853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
    Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
    Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
    Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C
    Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.